Last reviewed · How we verify
NCT00786058
A Phase III Second Line Trial of Patients With Gemcitabine Resistant Advanced Pancreatic Cancer (CONKO-003)
trial testing OFF in experimental arm in Pancreatic Cancer. Approved for marketing.
Quick facts
| Lead sponsor | CONKO-Studiengruppe |
|---|---|
| Status | APPROVED FOR MARKETING |
| Study type | EXPANDED_ACCESS |
Drugs / interventions tested
- OFF in experimental arm — full drug profile →
Conditions studied
- Pancreatic Cancer — all drugs for Pancreatic Cancer →
Sponsor
CONKO-Studiengruppe — full company profile →
Who can join
18 and older, any sex, with Pancreatic Cancer.
Sponsor's own description
The purpose of this study is to compare best supportive care plus oxaliplatin/ folinic acid/ 5-FU versus best supportive alone in patients with gemcitabine refractory pancreatic cancer.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Trial watch: Chemotherapy with immunogenic cell death inducers.
Vacchelli E, Galluzzi L, Fridman WH, Galon J, et al · · 2012 · cited 98× · PMID 22720239 · DOI 10.4161/onci.1.2.19026 -
Consensus, debate, and prospective on pancreatic cancer treatments.
Wang J, Yang J, Narang A, He J, et al · · 2024 · cited 56× · PMID 39390609 · DOI 10.1186/s13045-024-01613-x -
Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment.
Long SA, Amparo AM, Goodhart G, Ahmad SA, et al · · 2024 · cited 16× · PMID 38800401 · DOI 10.3389/fonc.2024.1402128 -
Metastatic Pancreatic Cancer: Where Are We?
Hernández-Blanquisett A, Quintero-Carreño V, Martínez-Ávila MC, Porto M, et al · · 2023 · cited 8× · PMID 38304752 · DOI 10.3389/or.2023.11364
Verify or expand the search:
- PubMed search for NCT00786058
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pancreatic Cancer
Currently open trials in the same condition.
- NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting
- NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
- NCT07236177 — B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosi · EARLY_PHASE1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00786058 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by CONKO-Studiengruppe
- Last refreshed: 12 June 2009
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00786058.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing